Subsequently, several carborane-containing AR ligands were developed as candidates for prostate cancer therapeutics.186, 187, 188 The carborane cage served as a hydrophobic pharmacophore for the AR ligand binding domain (AR LBD) of antagonists (33, 34) (Figure 6B).183. The gene discussed is AR; the disease is prostate carcinoma.